Trial · NCT00827918
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) at Week 4 | MK-8998 | -13.3 | 95% Confidence Interval -17.9 to -8.7 | Units on a scale | |
| Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) at Week 4 | Olanzapine | -17.0 | 95% Confidence Interval -22.8 to -11.1 | Units on a scale | |
| Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) at Week 4 | Placebo Comparator | -12.7 | 95% Confidence Interval -17.2 to -8.2 | Units on a scale | |
| Number of Participants Who Experienced at Least One Adverse Event | MK-8998 | 41 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event | Olanzapine | 23 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event | Placebo Comparator | 33 | Participants | ||
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | MK-8998 | 9 | Participants | ||
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | Olanzapine | 1 | Participants | ||
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | Placebo Comparator | 1 | Participants | ||
| Percentage of Participants With Response at Week 4 | MK-8998 | 57.4 | Percentage of participants | ||
| Percentage of Participants With Response at Week 4 | Olanzapine | 66.7 | Percentage of participants | ||
| Percentage of Participants With Response at Week 4 | Placebo Comparator | 48.3 | Percentage of participants | ||
| Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) at Week 4 | MK-8998 | -0.9 | 95% Confidence Interval -1.2 to -0.7 | Units on a scale | |
| Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) at Week 4 | Olanzapine | -0.8 | 95% Confidence Interval -1.2 to -0.5 | Units on a scale | |
| Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) at Week 4 | Placebo Comparator | -0.9 | 95% Confidence Interval -1.1 to -0.6 | Units on a scale | |
| Mean Change From Baseline in PANSS Positive Subscale at Week 4 | MK-8998 | -4.2 | 95% Confidence Interval -5.6 to -2.8 | Units on a scale | |
| Mean Change From Baseline in PANSS Positive Subscale at Week 4 | Olanzapine | -5.6 | 95% Confidence Interval -7.4 to -3.8 | Units on a scale | |
| Mean Change From Baseline in PANSS Positive Subscale at Week 4 | Placebo Comparator | -4.2 | 95% Confidence Interval -5.6 to -2.9 | Units on a scale | |
| Mean Change From Baseline in PANSS Negative Subscale at Week 4 | MK-8998 | -3.3 | 95% Confidence Interval -4.5 to -2.2 | Units on a scale | |
| Mean Change From Baseline in PANSS Negative Subscale at Week 4 | Olanzapine | -3.1 | 95% Confidence Interval -4.5 to -1.6 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00827918/results